Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat
- PMID: 25854989
- DOI: 10.1038/hr.2015.50
Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat
Abstract
Overactivity of the sympathetic nervous system has an important role in the development and progression of arterial hypertension. Catheter-based renal nerve ablation for the treatment of drug-resistant hypertension has recently been developed. An alternative strategy for the modulation of sympathetic nerve function is to reduce the biosynthesis of noradrenaline (NA) by inhibiting dopamine β-hydroxylase (DβH), the enzyme that catalyzes the conversion of dopamine (DA) to NA in the sympathetic nerves. Renal denervation (RDN) surgery was performed in spontaneously hypertensive rats (SHR) to evaluate the effect of RDN on the DA and NA levels and on blood pressure over a 28-day period. The selective peripheral DβH inhibitor etamicastat (30 mg kg (-1)day(-1)) was administered to another cohort of SHR. RDN and etamicastat treatment had no effect on the renal function, as assessed by measuring the water balance response, renal function and urinary electrolyte levels. RDN significantly decreased the systolic blood pressure (SBP) and the diastolic blood pressure (DBP). A gradual return of the SBP and the DBP to the high baseline levels was observed over time. Conversely, treatment with etamicastat resulted in a significant decrease in the SBP and the DBP at all time points. On the last day of the assessment, NA levels in renal tissue were significantly decreased in both RDN and etamicastat-treated groups. In contrast, the NA levels in the left ventricle were decreased only in the etamicastat-treated group. Thus, RDN produces transitory decreases in blood pressure, whereas prolonged downregulation of sympathetic drive with the DβH inhibitor etamicastat results in a sustained decrease in the SBP and the DBP.
Similar articles
-
Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.J Am Soc Hypertens. 2016 Mar;10(3):207-16. doi: 10.1016/j.jash.2015.12.011. Epub 2015 Dec 19. J Am Soc Hypertens. 2016. PMID: 26803288
-
Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.Eur J Pharmacol. 2014 Oct 5;740:285-94. doi: 10.1016/j.ejphar.2014.07.027. Epub 2014 Jul 21. Eur J Pharmacol. 2014. PMID: 25058908
-
Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.Eur J Pharmacol. 2015 Mar 15;751:50-8. doi: 10.1016/j.ejphar.2015.01.034. Epub 2015 Jan 29. Eur J Pharmacol. 2015. PMID: 25641750
-
Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.Curr Pharm Des. 1998 Dec;4(6):469-79. Curr Pharm Des. 1998. PMID: 10197057 Review.
-
Can we predict the blood pressure response to renal denervation?Auton Neurosci. 2017 May;204:112-118. doi: 10.1016/j.autneu.2016.07.011. Epub 2016 Jul 30. Auton Neurosci. 2017. PMID: 27530600 Free PMC article. Review.
Cited by
-
Effects of renal denervation on blood-pressure response to hemorrhagic shock in spontaneously hypertensive rats.Chin J Traumatol. 2018 Oct;21(5):293-300. doi: 10.1016/j.cjtee.2018.09.001. Epub 2018 Oct 1. Chin J Traumatol. 2018. PMID: 30342984 Free PMC article.
-
Effects of dopamine β-hydroxylase inhibition in pressure overload-induced right ventricular failure.Pulm Circ. 2024 Nov 13;14(4):e70008. doi: 10.1002/pul2.70008. eCollection 2024 Oct. Pulm Circ. 2024. PMID: 39539945 Free PMC article.
-
Sympathoinhibitory Effect of Radiofrequency Renal Denervation in Spontaneously Hypertensive Rats With Established Hypertension.Am J Hypertens. 2016 Dec 1;29(12):1394-1401. doi: 10.1093/ajh/hpw089. Am J Hypertens. 2016. PMID: 27538721 Free PMC article.
-
Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with β-receptor blockade.Hypertens Res. 2016 Apr;39(4):217-26. doi: 10.1038/hr.2015.133. Epub 2015 Dec 3. Hypertens Res. 2016. PMID: 26631854
-
Emerging Therapy in Hypertension.Curr Hypertens Rep. 2019 Mar 2;21(3):23. doi: 10.1007/s11906-019-0923-1. Curr Hypertens Rep. 2019. PMID: 30826948 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources